LIPO-202: Ph II LIPO-202-CL-31 started

Neothetics began the double-blind, placebo-controlled, U.S. Phase II LIPO-202-CL-31 trial to evaluate 0.3 and 3 µg doses of subcutaneous LIPO-202 weekly for 8 weeks in about 150 patients....